Transparency data: Non-tech summaries 2016: projects on nervous/mental disorders

Home Office Building - London - by .Martin. via Flickr
This article was originally published on this website



This document outlines the projects granted under the Animals (Scientific Procedures) Act 1986 during 2016 with a primary purpose of translational applied research – human nervous and mental disorders.

  • developing therapies for perinatal diseases (lack of oxygen, brain haemorrhage)

  • neurovascular function in health and disease (brain, blood vessels, alzheimer’s disease, energy, pericyte)

  • assessment of blood brain barrier transporters (drug discovery; blood brain barrier)

  • modulating autophagy tct tackle huntington’s disease (autophagy, cell death, huntington’s disease)

  • translational pharmacology for drug discovery (pharmacology, drug, discovery)

  • electrophysiological studies of neurodegenerative disorders (neurodegeneration, drug discovery, electrophysiology, in vivo)

  • anaesthesia and the developing brain (anaesthesia, neurodegeneration, neuro-apoptosis, developing brain)

  • gene transcription events mediating brain and behaviour (epigenetics; post-transcriptional modification; imprinted genes; behaviour; brain)

  • examining the role of mitochondria in neurodegeneration and vascular disorders (alzheimers, blood vessels, mitochondria, neurodegeneration)

  • using zebrafish to understand disease and develop therapies (zebrafish, development, disability, therapy, mechanism)

  • pharmacodynamics and pharmacokinetics of novel compounds (drug discovery, receptor, pharmacokinetic, pharmacodynamic)

  • MK2 as a regulator of inflammation in alzheimer’s (alzheimer’s, inflammation, hippocampus, synaptic plasticity, behaviour.)

  • neural signalling and disease in rodents (motoneurone, mechanosensation, MND, hypertension)

  • repair in neurodegenerative disease and injury (central nervous system, nerve cells, neurodegenerative diseases, regeneration)

  • role of D1R-D3R heteromers in l-DOPA-induced dyskinesias (parkinson’s disease, dyskinesia, dopamine, heteromers, glutamate receptors)

  • maintenance and regeneration of the nervous system (avulsion, neurodegeneration)

  • determination of CNS efficacy and safety pharmacology (central nervous system, behaviour, safety)

  • zebrafish and medaka as models for the study of psychiatric disease and age-related cognitive decline (zebrafish, behaviour, addiction, genetic modification, ageing)

  • early life exposure to drugs and environmental complexity and neuropsychiatric disorder (genetics, nature/nurture, environmental complexity)

  • neurological disorders: mechanisms and therapies (behaviour, cognition, brain, neurological disorder)

  • analgesic potential of retargeted SNARE proteases (analgesia, pain, neuropathic, post-operative, inflammatory)

  • CNS neurotransmitter action in health and disease (brain, neurodevelopmental disorders, neurodegeneration, neuron, glia)

  • improving the treatment of parkinson’s disease and parkinson’s disease dementia (parkinson’s disease, dementia, better treatments, cell protection, cell repair)

  • neuropharmacology and therapeutics in addiction and other dopamine-associated disorders (addiction, parkinson’s disease, treatments, neurogenesis)

  • Be the first to comment

    Leave a Reply